GlycoNet Investigator receives award to advance technologies for ‘Universal Donor’ O type blood

Michael Smith Laboratories • Posted: January 25, 2021

Dr. Stephen Withers is named one of nine recipients of the 2020 Innovation to Commercialization Program Award from the Michael Smith Foundation of Health Research

GlycoNet Investigator Dr. Stephen Withers from UBC receives the 2020 Innovation to Commercialization Program Award from the Michael Smith Foundation of Health Research.

Congratulations to GlycoNet Investigator Dr. Stephen Withers, Professor at the University of British Columbia, for being named one of nine recipients across British Columbia to receive a 2020 Innovation to Commercialization (I2C) Program Award. This award is granted from the Michael Smith Foundation for Health Research (MSFHR) to support researchers to advance their discoveries or inventions towards practical application, resulting in products or technologies that improve health outcomes and enrich BC’s health innovation ecosystem.

Withers’ funding award will assist in his research focusing on using new technologies in glycomics that act on A and B blood types to generate ‘Universal Donor’ O type blood, which is often found in short supply. 

Read the full announcement from the Michael Smith Laboratories.

Discover more from GlycoNet News.

© Réseau Canadien de la Glycomique (GlycoNet). Tous droits réservés.

fr_CAFrench
Scroll to Top